FAKTOR ZERTIFIKAT LONG - ASTRAZENECA | Market Closed - Borsa Italiana 13:15:54 2024-06-05 EDT | ||
| 41.52 EUR | +2.34% |
|
| Current month | +12.14% | ||
| 1 month | +15.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 41.52 | +2.34% |
| 24-06-04 | 40.57 | +3.36% |
| 24-06-03 | 39.25 | +5.88% |
| 24-05-31 | 37.07 | +8.55% |
| 24-05-30 | 34.15 | +5.17% |
Real-time Borsa Italiana
Last update June 05, 2024 at 01:15 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| SAZNL5 | |
| ISIN | DE000SW8FX82 |
| Date issued | 2024-04-08 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 42.02 € |
|---|---|
| Lowest since issue | 19.05 € |
| Spread | 1.2 € |
| Spread % | 2.84% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
172.9
USD
Spread / Average Target
+9.02%
- Stock Market
- Certificates
- SAZNL5 Certificat
